Vor Biopharma shareholders approved amended 2021 equity incentive plan at annual meeting

• Vor Biopharma held its annual shareholder meeting on June 11, 2026.
• Shareholders backed an amended and restated 2021 equity incentive plan, updating the annual share reserve increase calculation to include pre-funded warrant shares.
• The plan change also provides for accelerated vesting of outstanding, unvested time-based awards upon an employee participant’s death, unless an award agreement says otherwise.
• Shareholders ratified Ernst & Young as independent registered public accounting firm for 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vor Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-269431), on June 12, 2026, and is solely responsible for the information contained therein.